Follow AARDA
How You Can Help
Sign-up for Updates
Join Our Email List
Contact AARDA

National Office
22100 Gratiot Ave.
Eastpointe, MI 48021
586.776.3903 (fax)

Washington Office

Request Literature



Advocacy Issues

The American Autoimmune Related Diseases Association takes positions from time to time on health related issues and legislation.

Some of our recent efforts:

10/28/15 AARDA submitted comments to the FDA regarding Nonproprietary Naming of Biological Products; Draft Guidance for Industry.


9/17/15 The US Senate Committee on Health, Education, Labor, and Pensions conducted a hearing to assess the progress of the FDA in implementing biosimilars: “Biosimilars Implementation: A Progress Report from FDA”


7/25/15 AARDA’s president and executive director Virginia Ladd, pens OpEd which appeared in the Editorial Section of the Detroit News.


7/13/15 AARDA cosponsors Biosimilars Briefing on Capitol Hill.


6/23/15 AARDA is supportive of the 21st Century Cures Act. Here is one of many letters to which we have lent our name. [Update: The 21st Century Cures Act was overwhelmingly passed by the House on July 1oth]


6/16/15 AARDA and the NCAPG represents AD patients at the UN World Health Organization meeting in Geneva, Switzerland  on June 16, 2015. The meeting was on International Nonproprietary Names (INN) Biological Qualifiers (BQ) to continue its development of a worldwide accepted naming convention for biologic and biosimilar drugs.


6/01/15 AARDA’s Board of Directors approved a Policy Statement on Biologics


3/6/15  AARDA’s Statement on the FDA’s Approval of the First U.S. Biosimilar Drug


3/6/15 AARDA releases paper on Biologics-Biosimilars